State of New Jersey Common Pension Fund D Sells 31,221 Shares of ADMA Biologics Inc $ADMA

State of New Jersey Common Pension Fund D lessened its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 25.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,425 shares of the biotechnology company’s stock after selling 31,221 shares during the period. State of New Jersey Common Pension Fund D’s holdings in ADMA Biologics were worth $1,701,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ADMA. Intech Investment Management LLC boosted its stake in ADMA Biologics by 164.2% in the 1st quarter. Intech Investment Management LLC now owns 292,595 shares of the biotechnology company’s stock worth $5,805,000 after purchasing an additional 181,839 shares during the period. Strs Ohio bought a new stake in shares of ADMA Biologics in the first quarter valued at about $1,307,000. New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company’s stock valued at $4,402,000 after purchasing an additional 108,800 shares in the last quarter. Vident Advisory LLC bought a new stake in shares of ADMA Biologics in the first quarter valued at about $2,735,000. Finally, Caxton Associates LLP bought a new stake in shares of ADMA Biologics in the first quarter valued at about $668,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.4%

Shares of ADMA Biologics stock opened at $15.48 on Monday. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The stock has a market cap of $3.69 billion, a P/E ratio of 18.00 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is $15.61 and its 200-day moving average is $18.06.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 earnings per share. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.